Middleton & Co Inc MA lowered its position in shares of Celgene Corporation (NASDAQ:CELG) by 3.2% during the second quarter, Holdings Channel reports. The firm owned 1,743 shares of the biopharmaceutical company’s stock after selling 58 shares during the period. Middleton & Co Inc MA’s holdings in Celgene Corporation were worth $226,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Friess Associates LLC acquired a new position in Celgene Corporation during the fourth quarter worth approximately $15,056,000. Hampstead Capital LLP acquired a new position in Celgene Corporation during the fourth quarter worth approximately $4,630,000. Orbimed Advisors LLC increased its position in Celgene Corporation by 5.4% in the fourth quarter. Orbimed Advisors LLC now owns 3,106,777 shares of the biopharmaceutical company’s stock worth $359,609,000 after buying an additional 158,200 shares during the period. Soros Fund Management LLC acquired a new position in Celgene Corporation during the fourth quarter worth approximately $405,000. Finally, Alkeon Capital Management LLC increased its position in Celgene Corporation by 3.1% in the fourth quarter. Alkeon Capital Management LLC now owns 1,818,555 shares of the biopharmaceutical company’s stock worth $210,498,000 after buying an additional 55,460 shares during the period. 78.39% of the stock is currently owned by institutional investors and hedge funds.
Celgene Corporation (CELG) opened at 137.84 on Tuesday. The company has a 50 day moving average of $128.98 and a 200 day moving average of $122.58. The firm has a market capitalization of $107.63 billion, a PE ratio of 51.76 and a beta of 1.89. Celgene Corporation has a 1-year low of $96.93 and a 1-year high of $138.93.
Celgene Corporation (NASDAQ:CELG) last announced its earnings results on Thursday, April 27th. The biopharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.47 by $0.21. The business had revenue of $2.96 billion for the quarter, compared to analyst estimates of $3.04 billion. Celgene Corporation had a net margin of 18.32% and a return on equity of 70.94%. The company’s revenue for the quarter was up 17.8% compared to the same quarter last year. During the same period last year, the firm posted $1.32 earnings per share. Analysts forecast that Celgene Corporation will post $7.28 EPS for the current year.
ILLEGAL ACTIVITY WARNING: “Middleton & Co Inc MA Reduces Position in Celgene Corporation (NASDAQ:CELG)” was first published by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this story on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this story can be read at https://stocknewstimes.com/2017/07/25/middleton-co-inc-ma-reduces-position-in-celgene-corporation-nasdaqcelg.html.
CELG has been the topic of a number of research reports. Cann reissued a “buy” rating and set a $148.00 target price on shares of Celgene Corporation in a research report on Tuesday, April 4th. Oppenheimer Holdings, Inc. reissued an “outperform” rating and set a $148.00 target price on shares of Celgene Corporation in a research report on Wednesday, April 5th. Jefferies Group LLC reissued a “buy” rating and set a $154.00 target price on shares of Celgene Corporation in a research report on Tuesday, April 11th. Robert W. Baird reissued an “outperform” rating and set a $162.00 target price on shares of Celgene Corporation in a research report on Wednesday, April 19th. Finally, Barclays PLC reissued an “equal weight” rating and set a $125.00 target price (up previously from $120.00) on shares of Celgene Corporation in a research report on Sunday, April 23rd. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and twenty-two have issued a buy rating to the company. Celgene Corporation presently has an average rating of “Buy” and a consensus price target of $141.92.
In related news, insider Robert J. Hugin sold 175,970 shares of the stock in a transaction on Thursday, June 22nd. The stock was sold at an average price of $134.14, for a total transaction of $23,604,615.80. Following the completion of the sale, the insider now directly owns 1,033,909 shares of the company’s stock, valued at $138,688,553.26. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Rupert Vessey sold 4,785 shares of the stock in a transaction on Thursday, June 15th. The stock was sold at an average price of $120.18, for a total value of $575,061.30. Following the sale, the insider now directly owns 4,004 shares of the company’s stock, valued at $481,200.72. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 237,005 shares of company stock worth $31,515,142. Insiders own 0.95% of the company’s stock.
Celgene Corporation Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).
Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
